Physician profile
Nicholas A Maxwell
NPI 1194211144
$9,554.33
in general payments reported to CMS, 2019-2025
28 companies · $2,637 in 2025
The $2,637 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $834 · 2022: $1,713 · 2023: $2,033 · 2024: $2,337 · 2025: $2,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,882 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,881.68 |
| Education | $126.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,888.31 | 2021-2025 | |
| Janssen Biotech, INC. | $1,372.16 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $1,121.17 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $791.57 | 2022-2025 | |
| Ucb, INC. | $737.40 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $672.92 | 2022-2025 | Sotyktu |
| Pfizer INC. | $487.05 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $442.16 | 2021-2025 | Winlevi, Absorica Ld |
| Dermavant Sciences, INC. | $370.01 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $358.69 | 2022-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $302.41 | 2024-2025 | Zoryve |
| Amgen INC. | $223.92 | 2023-2025 | Otezla, Otezla |
| Genzyme Corporation | $157.79 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $116.04 | 2024-2025 | Tremfya |
| Janssen Scientific Affairs, LLC | $101.17 | 2024 | Tremfya |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $86.11 | 2022-2024 | Opzelura |
| Leo Pharma INC. | $74.98 | 2021-2025 | Adbry |
| Almirall LLC | $51.50 | 2024-2025 | Klisyri, Seysara |
| Galderma Laboratories, L.P. | $43.90 | 2021-2022 | |
| Biofrontera INC. | $25.22 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Optinose US, INC. | $24.57 | 2023 | |
| Kyowa Kirin, INC. | $23.50 | 2022 | |
| Hologic Sales and Service, LLC | $17.38 | 2023 | Coolseal Generator |
| Nabriva Therapeutics, Plc | $14.23 | 2022 | |
| Genentech USA, INC. | $14.01 | 2024 | Erivedge |
| Acclarent, INC | $13.67 | 2022 | |
| Intersect Ent, INC. | $11.87 | 2021 | |
| Organon LLC | $10.62 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Maxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.